The Filing Desk

Aardvark Therapeutics vs Genelux

Aardvark Therapeutics AARD · Genelux GNLX · Pharmaceuticals

Free cash flow was −$54 million at Aardvark Therapeutics and −$26 million at Genelux.

Side by side

Aardvark TherapeuticsGenelux
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth—0.0%
Revenue growth a year, last 5 years——
Gross margin——
Operating margin—−415,175.0%
Net margin—−401,812.5%
Free cash flow−$54M−$26M
Free cash flow margin—−329,575.0%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count391.1%18.2%
Last close$1.00$2.28
P/E at the last close——
Insider trades, last 12 monthsbought $144,630, sold $394,930sold $327,695
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aardvark TherapeuticsGenelux
Operating margin
Percent of revenue
Aardvark TherapeuticsGenelux
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aardvark TherapeuticsGenelux

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aardvark Therapeutics and Genelux pages.